You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》高盛上调诺诚健华-B(09969.HK)目标价至21元 评级「买入」
阿思达克 03-30 14:01
高盛发表研究报告指,诺诚健华-B(09969.HK)去年下半年录亏损5,700万元人民币,主要来自研发费用按年增长45%及营销及一般行政费用增长104%,但亏损已较2019年同期的2.43亿元人民币大幅减少。

该行指,诺诚健华在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想,正计划将销售团队扩充至200人,今年内覆盖内地900家医院。

另外,高盛认为今年下半年潜在的国家医保药品目录谈判或为诺诚健华今年的增长动力之一,参考市场上其他BTK抑制剂Brukinsa及Imbruvica定价,认为对BTK抑制剂市场价格有支持作用。

高盛对诺诚健华予以「买入」评级,以反映2月份配股所得资金,以及公司将於今明两年加大研发投入,但预期今年及明年净亏损5.85亿及3.01亿元人民币,目标价上调至21元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account